122 related articles for article (PubMed ID: 11593338)
21. [Cytotoxic Agents and Immune Checkpoint Inhibitors].
Kawazoe A; Shitara K
Gan To Kagaku Ryoho; 2017 Sep; 44(9):717-721. PubMed ID: 28912395
[TBL] [Abstract][Full Text] [Related]
22. [Trypanosa: enzyme and immunotherapy?].
Schweiz Rundsch Med Prax; 1987 Oct; 76(42):1176-8. PubMed ID: 3324261
[No Abstract] [Full Text] [Related]
23. Non-myeloablative stem-cell transplantation in the treatment of malignant and non-malignant disorders.
Shimoni A; Nagler A
Isr Med Assoc J; 2002 Apr; 4(4):272-9. PubMed ID: 12001702
[No Abstract] [Full Text] [Related]
24. Biological response modifiers.
Clark JW
Cancer Chemother Biol Response Modif; 1988; 10():434-59. PubMed ID: 3079394
[No Abstract] [Full Text] [Related]
25. Prodrug activation enzymes in cancer gene therapy.
Aghi M; Hochberg F; Breakefield XO
J Gene Med; 2000; 2(3):148-64. PubMed ID: 10894261
[TBL] [Abstract][Full Text] [Related]
26. Prodrugs for antibody- and gene-directed enzyme prodrug therapies (ADEPT and GDEPT).
Niculescu-Duvaz I; Friedlos F; Niculescu-Duvaz D; Davies L; Springer CJ
Anticancer Drug Des; 1999 Dec; 14(6):517-38. PubMed ID: 10834273
[TBL] [Abstract][Full Text] [Related]
27. Immunotherapy's cancer remit widens.
Ledford H
Nature; 2013 May; 497(7451):544. PubMed ID: 23719439
[No Abstract] [Full Text] [Related]
28. Biological Therapy of Cancer--From Basic Research to Clinical Application, the 3rd International Symposium. Munich, Germany, April 1995. Abstracts.
Eur J Cancer; 1995; 31A Suppl 3():S1-38. PubMed ID: 8554916
[No Abstract] [Full Text] [Related]
29. Immunotherapeutic strategies for neoplasia.
Talmadge JE
Dev Biol Stand; 1992; 77():17-28. PubMed ID: 1426659
[No Abstract] [Full Text] [Related]
30. Cancer gene therapy.
Douglas JT
Technol Cancer Res Treat; 2003 Feb; 2(1):51-64. PubMed ID: 12625754
[TBL] [Abstract][Full Text] [Related]
31. A symposium on cancer in children. Medical management.
Mitchell-Heggs P
Nurs Mirror Midwives J; 1977 Apr; 144(14):48-52. PubMed ID: 585064
[No Abstract] [Full Text] [Related]
32. Prodrug-activating systems in suicide gene therapy.
Springer CJ; Niculescu-Duvaz I
J Clin Invest; 2000 May; 105(9):1161-7. PubMed ID: 10791987
[No Abstract] [Full Text] [Related]
33. [Combination Therapy of Immune Checkpoint Inhibitors].
Kitano S
Gan To Kagaku Ryoho; 2017 Sep; 44(9):727-732. PubMed ID: 28912397
[TBL] [Abstract][Full Text] [Related]
34. Cutting edge meets clinic in treatment research.
Blume E
J Natl Cancer Inst; 1994 Dec; 86(24):1818-20. PubMed ID: 7527468
[No Abstract] [Full Text] [Related]
35. In pursuit of cancer metastasis therapy by bacteria and its biofilms: History or future.
Adnan M; Khan S; Al-Shammari E; Patel M; Saeed M; Hadi S
Med Hypotheses; 2017 Mar; 100():78-81. PubMed ID: 28236853
[TBL] [Abstract][Full Text] [Related]
36. Advances in cancer management--an essay on the application of basic science principles.
Costanzi JJ
Tex Rep Biol Med; 1979; 38():79-85. PubMed ID: 394379
[No Abstract] [Full Text] [Related]
37. Regulatory T cells, as a target in anticancer immunotherapy.
Enokida T; Nishikawa H
Immunotherapy; 2017 Jun; 9(8):623-627. PubMed ID: 28653572
[No Abstract] [Full Text] [Related]
38. Immunotherapy in anticancer responses.
Whelan M
Curr Opin Mol Ther; 2004 Feb; 6(1):8-9. PubMed ID: 15011775
[No Abstract] [Full Text] [Related]
39. Proceedings of the 3rd International Symposium on Cancer Metastasis and the Lymphovascular System: Basis for Rational Therapy. May 6-9, 2009, San Francisco.
J Surg Oncol; 2011 May; 103(6):463-641. PubMed ID: 21649955
[No Abstract] [Full Text] [Related]
40. Anticancer research: a few hints for discovery of new targets.
Lacal JC
Cancer Lett; 2004 Apr; 206(2):125-7. PubMed ID: 15013517
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
